Biointron Insights: Antibody Industry Report

04-Nov-2024 - This report aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September). Besides PiaSky, Vyloy, Imdelltra, Tribuvia, and ivonescimab, five more novel antibody drugs have been approved this year: Enlonstobart (Enshuxing), Donanemab (Kisunla), ...

Generative AI antibody design platform

Antiverse raises £3.5M

21-Oct-2024 - Antiverse, a techbio company designing antibodies for challenging targets, announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many ...

YUMAB cooperates with AI specialist

YUMAB and MOLCURE collaborate to advance zero-shot AI antibody discovery technology for undruggable targets

17-Oct-2024 - YUMAB GmbH, a antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc., an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. The ...

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

Novel and potentially groundbreaking therapeutic strategy

10-Jul-2024 - SciRhom GmbH announced the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including ...

Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs

17-Jun-2024 - Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension round was led by new investor Thuja Capital, and as part of the financing, Evan ...

Almost two million euros for biotech start-up

BMBF funds DKFZ spin-off for the development of an antibody therapy against pancreatic cancer

12-Jun-2024 - Panosome GmbH, a biotech company founded in Heidelberg in 2020, specializes in the development of monoclonal antibodies for a wide range of medical purposes. The basis for this is the VAST technology platform jointly developed by Panosome and DKFZ. Panosome now wants to use the VAST technology to ...

Bio-Techne announces new distribution agreement with Thermo Fisher Scientific

07-May-2024 - Bio-Techne Corporation to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024, Bio-Techne will enter into a strategic distribution agreement with Thermo Fisher Scientific in Europe. This partnership marks an important ...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

"DISCO is uniquely positioned to transform cancer care"

18-Jan-2024 - DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking thesurfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing ...

ETH spin-offs – an annual record set in 2023

A growing number of female founders

09-Jan-2024 - A total of 43 new spin-​offs were founded at ETH Zurich over the past year, a new record. A particularly large number of young companies were created in the areas of artificial intelligence and biotechnology. In addition, an increasing number of ETH spin-​offs are being set up by women. 43 new ...

Calypso Enters into Agreement to Be Acquired by Novartis

09-Jan-2024 - Calypso Biotech BV, a leader in the development of Interleukin15 (IL-15) targeted therapies, announced that it has entered into an agreement to be acquired by Novartis AG. Calypso’s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development ...